Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
multiple myeloma/febbre
Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 24 risultati
Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Nowadays, more and more patients are receiving anticancer treatment by mouth. In this context, the development of oral chemotherapy represents a challenge to our health system as it means adapting the hospital's organization and making it safer to manage patients who are becoming autonomous and
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Multiple Myeloma (MM) is a molecularly heterogeneous disease with a high degree of genomic instability. Despite improvements in event-free survival and overall survival with the use of autologous stem cell transplantation and novel agents, MM remains an incurable disease (1,2). The best induction
Tinostamustine Conditioning and Autologous Stem Cell
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Study Design (Methodology):
This is a 2-part, international, multi-center, open-label study of salvage treatment with tinostamustine conditioning followed by ASCT in patients with relapsed/ refractory multiple myeloma (MM). (ASCT is defined as salvage if the patient had already received a prior ASCT
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Background:
- Multiple myeloma (MM) is a malignancy of plasma cells.
- MM is nearly always incurable.
- T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
- Autologous T cells genetically modified to express CARs
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Phase I Study Design
• Phase I will follow a 3+3 dose escalation design to determine the RPTD of ixazomib in combination with ONC201 and Dexamethasone.
The dose escalation rules for the phase I portion of the study are as follows, escalating in cohorts of 3 patients per dose level including a
Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT
Solo gli utenti registrati possono tradurre articoli
Entra registrati
MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Clinical Background
Bone metastasis give rise to major complications that lead to significant morbidity and impairment of life quality. The most common primary for bone metastasis is prostate, lung and breast carcinoma. These three have the highest cancer incidence in the USA with up to 85%
Tocilizumab in Patients With Schnitzler's Syndrome
Solo gli utenti registrati possono tradurre articoli
Entra registrati
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Indication:
This study will include subjects that have relapsed and refractory multiple myeloma (RRMM) after treatment with at least 3 prior antimyeloma therapies, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD®) or after development of double-refractoriness to a both a PI
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Background
Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing hemagglutination and complement-mediated hemolysis. Anemia is severe in one-third of patients (hemoglobin level 8.0 g/dL or lower). Cold-induced
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND:
- Multiple myeloma (MM) is a malignancy of plasma cells.
- MM is nearly always incurable.
- T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
- Autologous T cells genetically modified to express CARs
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Multiple myeloma (MM) is one of the most common hematological diseases and besides the option of an allogeneic stem cell transplantation remains incurable.
Although autologous stem cell transplantation and new compounds such as bortezomib, thalidomide and lenalidomide have been implemented,
Meloxicam vs Placebo for Mobilization
Solo gli utenti registrati possono tradurre articoli
Entra registrati
After the screening procedures confirm that the participant is eligible to participate in the research study:
Because no one knows which of the study options is best, the participant will be "randomized" into one of the study groups:
- G-CSF with meloxicam
- G-CSF with placebo (pills with no
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Solo gli utenti registrati possono tradurre articoli
Entra registrati
PRIMARY ENDPOINTS:
Phase I • Determination of the MTD of the combination therapy
Phase II:
• Response rate (CR+PR)
SECONDARY ENDPOINTS:
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Time to Progression (TTP)
- Time to next therapy
A total of 56 patients may be enrolled in this
Il database di erbe medicinali più completo supportato dalla scienza
- Funziona in 55 lingue
- Cure a base di erbe sostenute dalla scienza
- Riconoscimento delle erbe per immagine
- Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
- Leggi le pubblicazioni scientifiche relative alla tua ricerca
- Cerca le erbe medicinali in base ai loro effetti
- Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti
Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate
